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High expression of transcription factor 4 (TCF4) is
an independent adverse prognostic factor in acute
myeloid leukemia that could guide treatment 
decisions
Mutations in transcription factor 4 (TCF4) have recently
been described in myeloid dysplastic syndromes (MDS)
and acute myeloid leukemia (AML). We analyzed the
impact of TCF4 mRNA expression on clinical outcome in
AML patients (n=525). Patients with high TCF4 expression
(TCF4high, defined as the 25% highest TCF4 expressors) had
a significantly worse overall survival (OS) and event-free
survival (EFS) than patients with lower TCF4 expression
(TCF4low) (5-year OS 18% vs. 44%, P<0.0001; 5-year EFS
15% vs. 34%, P<0.0001, respectively). This was confirmed
in an independent cohort (n=436). Multivariate analysis
showed that TCF4high is an independent prognostic factor
for OS and EFS in the whole cohort and in patients carrying
a normal karyotype. 
Importantly, TCF4high patients benefited most from an
allogeneic hematopoietic cell transplantation (HCT), com-
pared to an autologous HCT or additional chemotherapy
(CT) (5-year OS 39%, 8%, 10%, P<0.0001; 5-year EFS
31%, 0%, 10%, P=0.001, respectively), while TCF4low
patients seemed to benefit most from an autologous HCT,
compared to allogeneic HCT or additional CT (5-year OS:
61%, 45%, 39% P=0.002; 5-year EFS: 42%, 32%, 34%,
P=0.102, respectively). 
We demonstrate that high expression of TCF4 is an inde-
pendent adverse prognostic factor in AML that could guide
treatment decisions.
TCF4 plays a role in a variety of developmental process-
es, including hematopoiesis. TCF4 is part of the basic helix-
loop-helix (bHLH) class 1 family, also called E-proteins.
These E-proteins recognize an E-box DNA binding site
(CANNTG), which are present in a variety of tissue-specific
enhancers.1,2 Recently, Papaemmanuil and colleagues
reported mutations in TCF4 in MDS patients.3 A total of 9
mutations were found in 7 of the 738 (0.9%) sequenced
MDS patients. The TCF4 mutations were found in various
MDS subclasses. Mutations in TCF4 have also been report-
ed for AML cases (0.5%)4 and were associated with a poor
prognosis,5 suggesting a potential role of TCF4 in the
pathogenesis of these myeloid malignancies. Here we
report that TCF4mRNA expression levels are an independ-
ent prognostic factor in AML patients. 
TCF4 expression values measured using Affymetrix
HGU133 plus 2.0 arrays were derived from a database
which contains a cohort of 525 AML patients treated
according to HOVON protocols (AML -04, -04A, -29, -32,
-42, -43; available at http://www.hovon.nl).6 Both bone mar-
row aspirates or peripheral-blood samples (at the time of
diagnosis) have been analyzed. Blasts and mononuclear
cells were purified by Ficoll–Hypaque (Nygaard) centrifuga-
tion and cryopreserved. The AML samples contained 80-
100% blast cells after thawing, regardless of the blast count
at diagnosis. To determine the TCF4 expression, an average
of 5 probe sets (which bind at different locations of the
gene) were used. The microarray expression data were con-
firmed by qPCR (Online Supplementary Figure S1). In addi-
tion, the TCF4 expression levels of healthy CD34+ control
cells (hCD34+; n=11) and mononuclear cell fractions
derived from normal bone marrow (NBM; n=5) were avail-
able. A second, independent cohort of 436 AML patients
was used for validation.7 Patients were divided into genetic
risk groups according to the European LeukemiaNet (ELN)
guidelines.8
In the studied cohort of 525 AML patients, TCF4 is dif-
ferentially expressed in AML blasts compared to NBM and
hCD34+ (Figure 1A). To study the impact of TCF4 expres-
sion levels on survival, the cohort was divided on the basis
of differences in expression levels; expression below or
above the median, tertiles, quartiles, quintiles, sixtiles and
septiles. In all these cohorts, univariate analysis showed
that high expression of TCF4was associated with poor out-
come. The highest expressors of TCF4 showed a more than
2-fold shorter 5-year OS than the lowest expressors (Online
Supplementary Figure S2). Since we found that TCF4 expres-
sion is not normally distributed and because approximately
25% of the patients showed a much higher expression
(Figure 1B), a distribution of the cohort based on the high-
est 25% (TCF4high) and the lowest 75% TCF4 expression 
(TCF4low) was used for further analysis. Characteristics of
the patients in the TCF4low and TCF4high groups are described
in Online Supplementary Table S1. TCF4high patients more
often had high-risk cytogenetic abnormalities (P<0.0001),
FLT3-ITD (P<0.0001) and their morphology more frequent-
ly corresponded with M0 or M1 FAB-subgroups
(P<0.0001). TCF4low patients were more likely to have bial-
lelic CEBPA mutations (P=0.011). No associations between
TCF4 expression and age, sex, white blood cell (WBC)
count, or other cytogenetic or molecular abnormalities
could be identified. 
Survival analysis according to the Kaplan-Meier method
showed that TCF4high patients had a worse survival than
patients classified as TCF4low (5-year OS 18% vs. 44%,
P<0.0001; 5-year EFS 15% vs. 34%, P<0.0001, respectively)
(Figure 1C and D). We confirmed the impact of TCF4
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Table 1. Multivariate Cox's regression survival analysis. Factors predicting overall survival and event-free survival in acute myeloid leukemia
patients of the first cohort with available complete data of all cytogenetic and molecular parameters (n=506).
                                                            Overall survival (n=506)                                                 Event-free survival (n=506)
Variable                                        c2 (Wald) DF             P                  HR (95% CI)         c2 (Wald)      DF              P                 HR (95% CI)
Favorable ELN risk group8                    40.11 3           <0.0001                                                     36.75              3             <0.0001                           
Intermediate-I ELN risk group             16.55 1           <0.0001            1.92 ( 1.40 - 2.63)            13.12              1             <0.0001           1.72 (1.28 - 2.30)
Intermediate-II ELN risk group             9.36 1              0.002              1.65 (1.20 - 2.28)             9.05               1                0.003              1.58 (1.17 - 2.12)
Adverse ELN risk group                          39.36 1           <0.0001            3.01 (2.13 - 4.24)            36.49              1             <0.0001           2.72 (1.97 - 3.76)
Age (>60 years)                                        18.06 1           <0.0001            1.81 (1.41 - 2.52)             9.82               1                0.002              1.57 (1.18 - 2.08)
WBC (>100 *109)                                      11.02 1              0.001               1.59 (1.21 - 2.09)            14.78              1             <0.0001           1.66 (1.28 - 2.15)
TCF4high expression                                   16.07 1           <0.0001            1.65 (1.29 - 2.11)            14.86              1             <0.0001           1.59 (1.26 - 2.02)
OS: overall survival; EFS: event-free survival; ELN: European LeukemiaNet8; DF: degrees of freedom; HR: Hazard Ratio; CI: Confidence Interval; WBC: white blood cell count.
expression levels on survival in the second cohort of 436
AML patients7 (OS: P=0.001; EFS: P<0.0001) (Online
Supplementary Figure S3). In the multivariate Cox regression
analysis, patients classified as TCF4high had a significantly
higher risk of death (HR 1.7, CI: 1.3–2.1; P<0.0001), relapse
or not obtaining a CR than TCF4low patients (HR 1.6, CI:
1.3–2.0; P<0.0001) (Table 1A). In addition, multivariate
Cox regression analysis revealed TCF4 expression, as a
continuous variable per 100 arbitrary units (AU), was a sig-
nificant predictor of OS and EFS (HR 1.04, CI: 1.01-1.07,
P=0.024; HR 1.05, CI: 1.02-1.08, P=0.002, respectively)
(Online Supplementary Table S2A). When selecting for AML
patients with a normal karyotype, TCF4high patients again
showed a worse OS and EFS than TCF4low patients (5-year
OS 21% vs. 41%, P<0.0001; 5-year EFS 18% vs. 33%,
P<0.0001, respectively) (Online Supplementary Figure S4). In
the multivariate Cox regression analysis of normal kary-
otype AML patients, TCF4 expression is also an independ-
ent predictor of survival (OS: HR 1.7, CI: 1.2-2.5, P=0.003;
EFS: HR 1.7, CI: 1.2–2.4, P=0.005) (Online Supplementary
Table S2B). Also as a continuous variable, TCF4 expression
remained an independent prognostic factor in this cohort
(OS: HR 1.07 (per 100 AU), CI: 1.02-1.13, P=0.004; EFS: HR
1.08 (per 100 AU), CI: 1.03-1.13, P=0.003) (Online
Supplementary Table S2C).
Interestingly, survival analysis according to the Kaplan-
Meier method showed that TCF4high and TCF4low patients of
the first cohort demonstrated a different survival benefit
depending on the consolidation treatment they received,
i.e, an additional cycle of chemotherapy (CT), autologous
or allogeneic hematopoietic cell transplantation (autoHCT,
alloHCT, respectively) (OS: Figure 1E and F; EFS: Online
Supplementary Figure S5). TCF4high patients who received
alloHCT showed a superior survival compared to TCF4high
patients who received autoHCT or who received additional
CT (5-year OS 39%, 8%, 10%, P<0.0001; 5-year EFS 31%,
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Figure 1. TCF4 expression and survival
curves in the first cohort. (A) Expression
of TCF4 in AML patients (n=525), NBM
(n=5) and hCD34+ (n=11). (B) TCF4
expression ranked from lowest to high-
est expression (n=525). (C) Overall sur-
vival (OS) curves for AML patients with
available follow-up data (n=518) strati-
fied by TCF4high (n=129) and TCF4low
(n=389). (D) Same for event-free sur-
vival (EFS). (E) OS curves for TCF4high
AML patients with available follow up
and consolidation treatment data
(n=129) stratified for conditioning with
alloHCT (n=36), autoHCT (n=13) or
additional CT (n=80). (F) OS curves for
TCF4low AML patients with available fol-
low up and consolidation treatment
data (n=386) stratified for conditioning
with alloHCT (n=99), autoHCT (n=57) or
additional CT (n=212).
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0%, 10%, P=0.001, respectively). In contrast, patients clas-
sified as TCF4low showed a trend towards significant superi-
or survival after autoHCT, compared to TCF4low patients
who received alloHCT or additional CT (5-year OS: 61%,
45%, 39% P=0.002; 5-year EFS: 42%, 32%, 34%, P=0.102,
respectively). Moreover, this difference in outcome,
depending on type of consolidation treatment between the
TCF4high and the TCF4low patients, was confirmed in multi-
variate Cox regression analysis (Online Supplementary Table
S3). In the second cohort, only 7 patients in the TCF4high
group received autoHCT, hampering validation of our
observations in this subgroup. Nevertheless, also in this
cohort, consolidation treatment with alloHCT (n=44)
resulted in significantly better OS for TCF4high patients com-
pared to TCF4high patients who received additional
chemotherapy (n=58) (5-year OS 41% vs. 8%, respectively;
P<0.0001). Furthermore, in this cohort TCF4low patients
who received autoHCT (n=52) showed a superior OS com-
pared with those patients who received alloHCT (n=86) or
additional CT (n=186) (5-year OS 61%, 48% vs. 26%,
respectively; P<0.0001), confirming the observations from
the first cohort. 
The biological role of TCF4 is poorly understood,2 and
contrasting observations are described in the literature. For
example, enforced expression of members of the bHLH
class A family, including TCF4, suppresses colony-forming
efficiency of various cell lines due to upregulation of p21,
p15 and p16, suggesting that these bHLH proteins act as
negative regulators of cell growth.9 In contrast, Tcf4 expres-
sion appeared increased in rat-E1A-immortalized RK3E
cells following β-catenin induced neoplastic transformation
and aberrant expression of Tcf4 promoted neoplastic trans-
formation of RK3E cells.10 These different observations
might be explained by differences in cellular context, or by
the different transcript variants of TCF4,11-14 which could
affect the function of the protein.10 Possibly, TCF4 can
either stimulate or inhibit cell growth, depending on its
environment, which might indicate that an aberrant
expression is not only a prognostic marker, but also a
pathological feature. This would be in line with the report
of mutations in TCF4 in MDS and AML.3,4 
TCF4 has also been reported to be highly expressed in
hematopoietic stem cells (HSC) and to show a decreased
expression in committed progenitors.15 Since the frequency
of TCF4 mutations is relatively low (0.5% in AML), obvi-
ously not all patients with high expression of TCF4 can
have mutated TCF4. Interestingly, in MLL-AF9-mediated
transformation of progenitor cells, TCF4 has been shown
to be up-regulated.15 In the first cohort, patients with high
TCF4 expression are significantly more classified in the M0
or M1 FAB-subgroups than TCF4low patients, suggesting that
the leukemic cells of the TCF4high patients derive from more
immature cells. In addition, TCF4 expression of patients in
the TCF4high group is comparable to the level of TCF4
expression of hCD34+ cells. Furthermore, when looking at
the CD34 mRNA expression in the first cohort, 73.3% of
the TCF4high patients show a high CD34 expression (above
the median), compared to 42.1% of the TCF4low patients.
When including CD34 expression in the multivariate Cox
regression analysis, CD34 expression is an independent
prognostic factor in OS and EFS; nevertheless TCF4 expres-
sion also remains an independent prognostic factor (data not
shown). 
Our observations report on the prognostic relevance of
the level of TCF4 expression in AML and demonstrate that
high TCF4 expression is associated with a worse survival.
In addition, the TCF4 expression levels seem to provide
additional information in the response to treatment. Before
considering TCF4 expression levels in clinical decision-
making, additional validation studies, also to define opti-
mal cut-off levels, are needed. Further mechanistic studies
are warranted on the role of TCF4 in myeloid diseases.  
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